Table 2.
Variant | Growth on 1% SDS (Tat translocation) |
Mean M.I.C. for ampicillin (Sec translocation) |
---|---|---|
wild type | Y | 7.6 ± 0.9 |
5 residue truncations | ||
∆118–122 | Y | 10.0 ± 2.3 |
∆123–127 | Y | 5.3 ± 2.3 |
∆128–132 | Y | 12.0 ± 0.0 |
∆133–137 | Y | 6.7 ± 2.3 |
∆138–142 | Y | 7.0 ± 2.0 |
∆143–147 | Y | 6.7 ± 2.3 |
∆148–152 | Y | 10.0 ± 3.3 |
∆153–157 | Y | 9.6 ± 3.6 |
10 residue truncations | ||
∆118–127 | Y | 6.0 ± 0.0 |
∆128–137 | Y | 9.5 ± 3.0 |
∆138–147 | Y | 8.0 ± 0.0 |
∆148–157 | Y | 9.3 ± 2.3 |
15 residue truncations | ||
∆118–132 | Y | 9.0 ± 3.8 |
∆123–137 | Y | 8.0 ± 0.0 |
∆128–142 | Y | 10.0 ± 2.3 |
∆133–147 | Y | 9.3 ± 2.3 |
∆138–152 | Y | 5.0 ± 1.4 |
∆143–157 | Y | 4.8 ± 1.5 |
20 residue truncations | ||
∆118–137 | Y | 7.3 ± 1.2 |
∆138–157 | Y | 5.5 ± 1.9 |
25 residue truncations | ||
∆118–142 | Y | 12.0 ± 0.0 |
∆123–147 | Y | 7.6 ± 0.9 |
∆128–152 | Y | 8.0 ± 0.0 |
∆133–157 | Y | 6.0 ± 0.0 |
30 residue truncations | ||
∆118–147 | Y | 10.0 ± 2.8 |
∆123–152 | Y | 13.6 ± 2.2 |
∆128–157 | Y | 7.3 ± 1.2 |
>35 residue truncations | ||
∆118–152 | Y | 12.0 ± 0.0 |
∆123–157 | N | 3.0 ± 0.0 |
∆118–153 | Y | 16.0 ± 0.0 |
∆118–154 | Y/N | 9.3 ± 2.3 |
∆118–155 | N | 4.0 ± 0.0 |
∆118–156 | N | 4.0 ± 0.0 |
∆118–157 | N | 2.5 ± 0.6 |